Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graham M Wheeler

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Statistical Papers (Berlin, Germany)|June 8, 2018
Incoherent dose-escalation in phase I trials using the escalation with overdose control approachGraham M Wheeler
Statistics in Medicine|November 17, 2022
"Improving the performance of Bayesian logistic regression model with overdose control in oncology dose-finding studies" by Hongtao Zhang, Alan Chiang, and Jixian WangAlexia Iasonos, Graham M Wheeler
Journal of the Royal Statistical Society. Series C, Applied Statistics|March 19, 2019
A Bayesian model-free approach to combination therapy phase I trials using censored time-to-toxicity dataGraham M Wheeler, Michael J Sweeting, Adrian P Mander
Plos One|July 13, 2016
AplusB: A Web Application for Investigating A + B Designs for Phase I Cancer Clinical TrialsGraham M Wheeler, Michael J Sweeting, Adrian P Mander
Statistics in Medicine|March 16, 2017
Toxicity-dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trialsGraham M Wheeler, Michael J Sweeting, Adrian P Mander
Pharmaceutical Statistics|April 19, 2026
A Dose-Finding Design for Drug Combinations Using a Bayesian 4 Parameter Logistic Model With Penalised D-OptimalityMaxine Ajimi, Benjamin Webb, Graham M Wheeler, et al.
BMC Medicine|November 19, 2020
Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designsThomas Burnett, Pavel Mozgunov, Philip Pallmann, et al.
Nature Reviews. Clinical Oncology|March 20, 2013
Adaptive designs for dual-agent phase I dose-escalation studiesJennifer A Harrington, Graham M Wheeler, Michael J Sweeting, et al.
Statistics in Medicine|February 20, 2016
Modelling semi-attributable toxicity in dual-agent phase I trials with non-concurrent drug administrationGraham M Wheeler, Michael J Sweeting, Adrian P Mander, et al.
Clinical Trials (London, England)|December 21, 2019
Designing and evaluating dose-escalation studies made easy: The MoDEsT web appPhilip Pallmann, Fang Wan, Adrian P Mander, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Statistical Papers (Berlin, Germany)|June 8, 2018
Incoherent dose-escalation in phase I trials using the escalation with overdose control approachGraham M Wheeler
Statistics in Medicine|November 17, 2022
"Improving the performance of Bayesian logistic regression model with overdose control in oncology dose-finding studies" by Hongtao Zhang, Alan Chiang, and Jixian WangAlexia Iasonos, Graham M Wheeler
Journal of the Royal Statistical Society. Series C, Applied Statistics|March 19, 2019
A Bayesian model-free approach to combination therapy phase I trials using censored time-to-toxicity dataGraham M Wheeler, Michael J Sweeting, Adrian P Mander
Plos One|July 13, 2016
AplusB: A Web Application for Investigating A + B Designs for Phase I Cancer Clinical TrialsGraham M Wheeler, Michael J Sweeting, Adrian P Mander
Statistics in Medicine|March 16, 2017
Toxicity-dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trialsGraham M Wheeler, Michael J Sweeting, Adrian P Mander
Pharmaceutical Statistics|April 19, 2026
A Dose-Finding Design for Drug Combinations Using a Bayesian 4 Parameter Logistic Model With Penalised D-OptimalityMaxine Ajimi, Benjamin Webb, Graham M Wheeler, et al.
BMC Medicine|November 19, 2020
Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designsThomas Burnett, Pavel Mozgunov, Philip Pallmann, et al.
Nature Reviews. Clinical Oncology|March 20, 2013
Adaptive designs for dual-agent phase I dose-escalation studiesJennifer A Harrington, Graham M Wheeler, Michael J Sweeting, et al.
Statistics in Medicine|February 20, 2016
Modelling semi-attributable toxicity in dual-agent phase I trials with non-concurrent drug administrationGraham M Wheeler, Michael J Sweeting, Adrian P Mander, et al.
Clinical Trials (London, England)|December 21, 2019
Designing and evaluating dose-escalation studies made easy: The MoDEsT web appPhilip Pallmann, Fang Wan, Adrian P Mander, et al.
Pageof 2